Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab vs Nivolumab in dMMR Recurrent Endometrial Carcinoma
NCT05112601Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2022
- Primary completion
- Jul 2032
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in endometrial carcinoma, sponsored by National Cancer Institute. Started Jun 2022; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT05112601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112601.